首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1528971

支氣管擴張劑市場規模 - 按藥物類別、給藥途徑、應用、配銷通路、最終用途 - 全球預測

Bronchodilators Market Size - By Drug Class, Route of Administration, Application, Distribution Channel, End-Use - Global Forecast

出版日期: 2024年05月08日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於全球氣喘、慢性阻塞性肺病 (COPD) 和支氣管炎等呼吸系統疾病盛行率不斷上升，支氣管擴張劑市場規模在 2024 年至 2032 年間複合年成長率將達到 4.9%。根據世界衛生組織的數據，估計約有 3.92 億人患有慢性阻塞性肺病。由於空氣污染、吸煙和人口老化等因素，這些情況持續升級，對能夠緩解症狀和改善患者生活品質的有效藥物的需求不斷成長。

吸入裝置和製劑的技術進步正在擴大支氣管擴張劑治療的可近性和有效性。乾粉吸入器 (DPI)、定量吸入器 (MDI) 和霧化器的創新為患者提供了更方便、更精確的支氣管擴張藥物輸送方法。正在進行的研發工作重點是開發安全性更高、效果更持久的新型支氣管擴張劑療法，將進一步推動市場成長。

整個產業分為藥品類別、給藥途徑、應用、配銷通路、最終用途和地區。

根據藥物類別，黃嘌呤細分市場的支氣管擴張劑市場規模預計到 2032 年將錄得強勁成長，因為其在治療哮喘和慢性阻塞性肺病等慢性呼吸道疾病方面的功效已被證實。黃嘌呤衍生物，如茶鹼，透過放鬆氣道平滑肌來改善氣流並減輕症狀，如喘息和呼吸短促。這些藥物也用作維持治療，以控制患者症狀並防止病情惡化。

由於氣喘應用領域的支氣管擴張劑在全球範圍內的盛行率不斷增加，預計 2024 年至 2032 年期間將出現大幅複合年成長率。支氣管擴張劑透過放鬆氣道周圍的肌肉來改善氣流並緩解急性呼吸困難，從而幫助控制氣喘症狀。隨著醫療保健系統專注於改善氣喘管理和減少住院治療，對針對氣喘治療的有效支氣管擴張藥物的需求將繼續上升。

亞太地區支氣管擴張劑產業將在 2024 年至 2032 年間實現強勁成長。這推動了對有效治療方案的需求。各國政府也致力於透過宣傳活動和醫療改革來改善呼吸道疾病管理，進一步促進區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 氣喘和慢性阻塞性肺病等呼吸系統疾病的盛行率不斷增加
  - 持續的研發工作和新產品批准
  - 支氣管擴張劑的標籤外使用
- 產業陷阱與挑戰
  - 嚴格的監管框架
成長潛力分析
監管環境
技術景觀
波特的分析
PESTEL分析
未來市場趨勢

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按藥品類別，2021 - 2032 年

主要趨勢
BETA-腎上腺素能支氣管擴張劑
抗膽鹼能支氣管擴張劑
黃嘌呤衍生物
其他藥物類別

第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年

主要趨勢
口服
可注射
吸入
其他給藥途徑

第 7 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
氣喘
慢性阻塞性肺病（COPD）
其他應用

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 9 章：市場估計與預測：依最終用途，2021 - 2032 年

主要趨勢
醫院
專科診所
其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

AstraZeneca
Boehringer Ingelheim International GmbH
Cipla Inc.
GlaxoSmithKline plc
Glenmark Pharmaceuticals Limited
Innoviva
Medline Plus
Merck & Co.,
Mylan N.V.
Novartis AG
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd

簡介目錄

Product Code: 9421

Bronchodilators market size will register a 4.9% CAGR between 2024 and 2032 driven by the increasing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis globally. As per WHO, approximately 392 million people are estimated to be living with COPD. With these conditions continuing to escalate due to factors like air pollution, smoking, and aging populations, there is growing demand for effective medications that can alleviate symptoms and improve the quality of life for patients.

Technological advancements in inhalation devices and formulations are expanding the accessibility and efficacy of bronchodilator treatments. Innovations in dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers are offering patients more convenient and precise delivery methods for bronchodilator medications. The ongoing R&D efforts focused on developing novel bronchodilator therapies with improved safety profiles and longer-lasting effects will further drive the market growth.

The overall industry is classified into drug-class, route of administration, application, distribution channel, end-use, and region.

Based on drug class, the bronchodilators market size from the xanthine segment is slated to record a strong growth rate through 2032 due to its established efficacy in managing chronic respiratory conditions like asthma and COPD. Xanthine derivatives, such as theophylline, work by relaxing the smooth muscles in airways to improve airflow and reducing symptoms, such as wheezing and shortness of breath. These medications are also used as maintenance therapy to control symptoms and prevent exacerbations in patients.

Bronchodilators market from the asthma application segment is projected to observe a substantial CAGR during 2024-2032 owing to its increasing prevalence worldwide. Bronchodilators help in managing asthma symptoms by relaxing the muscles around the airways to improve airflow and alleviate acute breathing difficulties. As healthcare systems focus on improving asthma management and reducing hospitalizations, the demand for effective bronchodilator medications tailored to asthma treatment will continue to rise.

Asia Pacific bronchodilators industry will witness a robust growth rate between 2024 and 2032. Rapid urbanization and industrialization in countries like China and India are making way for higher levels of air pollution, leading to greater incidence of respiratory conditions. This is driving the need for effective treatment options. Governments are also focusing on improving respiratory disease management through awareness campaigns and healthcare reforms, further boosting the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of respiratory disorders such as asthma and COPD
  - 3.2.1.2 Ongoing R&D efforts and new product approvals
  - 3.2.1.3 Off-label use of bronchodilators
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug-class, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Beta-adrenergic bronchodilators
5.3 Anticholinergic bronchodilators
5.4 Xanthine derivatives
5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Injectable
6.4 Inhaled
6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Asthma
7.3 Chronic obstructive pulmonary disease (COPD)
7.4 Other application

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals
9.3 Specialty clinics
9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Italy
- 10.3.5 Spain
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa